Anemia Clinical Trial
Official title:
An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy
116 eligible patients with confirmed non-metastatic colorectal adenocarcinoma and anemia
will be randomized to receive either oral ferrous sulphate (control) or intravenous ferric
carboxymaltose (intervention).
It is hypothesized that intravenous iron supplementation is more efficacious than oral iron
therapy.
Patients who are anemic at the time of operation have been shown to have an increased
frequency of complications including wound infection and longer post-operative admissions.
Similarly, patients who are anemic at the time of their cancer operation are more likely to
require a blood transfusion which may increase the risk of recurrence of the cancer.
At present, oral iron is often used to treat anemia preoperatively in an attempt to minimize
the risk above. This drug is often poorly tolerated due to the side effect profile. Blood
transfusions can also be administered but expose the patient to other risks including
infection and transfusion associated reactions. In order to overcome these issues,
intravenous iron preparations have been developed and have improved in safety.
This is a multi-center, randomized, open label clinical trial, which looks to investigate
the efficacy of intravenous iron is in the treatment of preoperative anemia in colorectal
patients. Patients will be randomized to receive intravenous ferric carboxymaltose
(treatment group) or oral ferrous sulphate (control). The outcomes reviewed will include the
amount and frequency of blood transfusions received, changes in patient blood profiles,
patient quality of life scores, operative complications and hospital length of stay. The
role of hepcidin as a biomarker of treatment response will also be assessed.
The primary hypothesis to be tested is that intravenous iron will decrease transfusion
rates. To detect a significant clinical difference in blood transfused consistent with
previous published data (1 unit), 58 patients will be required in each arm of the study with
90% power (alpha 0.05).
Randomization will be performed independently to the trial team using a computer generated
variable block randomization program.
All data will be confidentially recorded on a Case Report Form, as will drug reactions and
side effects.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |